Huge mistake to sell. I may still reenter(at 20 LOL!!!). I still think the Japanese company partnership is a very big deal. I think in their private discussions with AFMD they may have gotten non-public information with non-disclosure agreements. The Japanese company is fairly small; they wouldn't part with 15 million without a reasonable basis for success. I may have lost out on AFMD, but as a Neurologist, I pray that VB-111 hits the big time next year to expand options for rGBM patients. Look at SAGE, is a postpartum depression treatment worth 3-4 billion in market cap??? with an infusion of 60 hours? I sold based on my analysis of public threads on Inspire/Facebook/blogs of about 12 VB111 patients, or about 10 % of study patients. Another positive point, the company knows more than we can every know about how the trial is doing, would they really open a manufacturing center now? if the y knew the drug was questionable?
I think the stock could rise to 10-12 over the next few months awaiting unblinding early next year. What is the wrinkle in the near term? Only one. If I were VBLT, I would raise additional monies in a financing prior to unblinding to move forward with ovarian, move forward with POC in their other oncology target, and perhaps do more preclinical work on NASH. I am anticipating a financing in the near term. It would make sense to do so, UNLESS they were certain as to the signal they are seeing. In that case, you would wait until next year for a follow up financing.
